FCGRT and chronic inflammatory demyelinating polyradiculoneuropathy: CIDP is a treatable yet disabling disorder, with a high response rate, but often suboptimal, to available first-line treatments including IVIG, SCIG, corticosteroids, plasma exchange and the recently approved FcRn inhibitor, efgartigimod.